Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Feb 01, 2021 4:25pm
152 Views
Post# 32439616

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dumping 20M shares and keeping 10M warrants @$3.18I've lurked on a few CYTO boards to see what holders and bashers say. The current "big event" they are all keyed on is this Covid trial for leronlimab (newly renamed something else like Viryologic) in severe Covid patients.  The trial is something like 2-300 with placebo.  The bashers point out monoclonal antibodies have a hard time around acute inflammation and are better at chronic inflammation.  The bulls just focus on the science from a small trial and some positive clues the doctors working on the trial have said.  The interesting thing is the bulls admit the CEO is way too promotional, sells shares, is a bit of a questionable character, but they like the actual science behind a CCR5 inhibitor.  That's all they hang their hat on and they ignore the bizarre capital raising with SEC-barred "toxic lenders".  So I guess the only lesson we can say is that massive PR and transparency seems to overcome those issues and they have at least presented the science clearly enough that they have believers.  But who knows, if the trial comes back that 50% of severe Covid patients were "cured", I guss that puts it in the category of Remdesivir, so not much of an improvement.  I'm sure the share will skyrocket on a 50% efficacy though since it would at least bolster the bulls science argument.   I'm not sure the real lessons other than they've somehow created an audience despite the horrible governance optics.

Bucknelly21 wrote: I'm curious about the cydy credibility argument, the market seems to trust them yet everyone here says corruption is the root of their company. The more I see things like this the less faith I have in Thtx to be honest. They get credit for everything they do yet we get nothing and we are apparently the squeaky clean company 


<< Previous
Bullboard Posts
Next >>